Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0M4MG
|
|||
| Former ID |
DNCL001871
|
|||
| Drug Name |
Resten-NG
|
|||
| Synonyms |
Resten-NG (TN)
Click to Show/Hide
|
|||
| Drug Type |
Antisense drug
|
|||
| Indication | Coronary artery disease [ICD-11: BA80; ICD-10: I25.1] | Phase 2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 2 | [1] | ||
| Company |
Cook Pharmica
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Technology evaluation: AVI-4126, AVI BioPharma. Curr Opin Mol Ther. 2004 Oct;6(5):551-8. | |||
| REF 2 | Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheter Cardiovasc Interv. 2001 Oct;54(2):247-56. | |||
| REF 3 | Complete vascular healing and sustained suppression of neointimal thickening after local delivery of advanced c-myc antisense at six months follow-up in a rabbit balloon injury model. Cardiovasc Radiat Med. 2002 Jan-Mar;3(1):26-30. | |||
| REF 4 | Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model. J Am Coll Cardiol. 2002 May 15;39(10):1686-91. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.